Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer
The combination of abemaciclib and trastuzumab improved survival rates in women with HR+, HER2+ advanced breast cancer compared to chemotherapy plus trastuzumab, with a manageable safety profile.